(P069) Gleason 7 Prostate Adenocarcinoma Treated With High- or Low-Dose-Rate Brachytherapy: Impact of External Beam Radiotherapy and/or Androgen Deprivation Therapy
nPSA has been related to biochemical progression–free survival, freedom from metastasis, and death from prostate cancer. BT with either EBRT or HT achieves a lower PSA nadir. There was no difference in disease failure. Longer follow-up may be necessary to see differences in disease failure in this population.
Julian Johnson, MD, Charles Hsu, I-Chow Hsu, MD, Vivian K. Weinberg, PhD, Alexander Gottschalk, MD, PhD, Barby Pickett, MS, Mack Roach; University of California, San Francisco; Texas Oncology
PURPOSE: To determine the impact of hormone therapy (HT) and/or external beam radiotherapy (EBRT) on prostate-specific antigen (PSA) nadir (nPSA) in patients with Gleason score (GS) 3 + 4 or 4 + 3 prostate cancer treated with low-dose-rate (LDR) or high-dose-rate (HDR) brachytherapy (BT) at a single institution.
MATERIALS AND METHODS: A total of 148 men were retrospectively identified with GS 7 (21% GS4 + 3, 79% GS3 + 4) cT1–T2cN0 prostate cancer receiving LDR (76%) or HDR (24%) BT as a component of treatment. LDR or HDR monotherapy was administered to 29% (EBRT was administered in 58%; HT was administered to 51%). Median follow-up from BT until last PSA or death was 72 months (range: 1–141 mo). nPSA was defined as current postimplant PSA nadir as of last visit. Disease failure was defined as PSA failure, local recurrence, metastasis, or salvage therapy.
RESULTS: Median time to nPSA was 43.4 months vs 29.8 months for patients treated with LDR vs HDR (P = .03). Patients treated with HDR were more likely to have T2 disease (P = .01) and had higher median baseline PSA (8.6 vs 6.2 ng/mL; P = .004). Patients treated with HDR were more likely to receive HT (42% vs 69%; P = .01) but not EBRT (54% vs 61%; P = .56). There was no statistically significant difference between nPSA after LDR vs HDR (median: 0.1 vs 0.1 ng/mL; P = .27). Median nPSA after LDR for GS 3 + 4 vs 4 + 3 was 0.1 ng/mL and 0.05 ng/mL, respectively (P = .32). Median nPSA after HDR for GS 3 + 4 vs GS 4 + 3 was 0.1 vs 0.06 ng/mL, respectively (P = .62). Treatment with HT resulted in a median nPSA of 0.045 vs 0.1 ng/mL (P < .0001). EBRT resulted in median nPSA of 0.06 ng/mL vs 0.1 ng/mL (P = .05). Patients treated with LDR brachytherapy had a lower nPSA if treated with HT (0.05 ng/mL vs 0.1 ng/mL; P = .0002). HT did not result in a lower nPSA in patients treated with HDR (P = .18). There was a statistically significant lower nPSA among LDR patients when combined with EBRT vs no EBRT (0.05 ng/mL vs 0.1 ng/mL; P = .003) but not among HDR patients (P = .52). Freedom from disease failure rate at 5 years was 92% vs 94% for LDR vs HDR, respectively (P = .00). There was no statistically significant difference with ADT (95% vs 89%; P = .33) or with EBRT (93% vs 91%; P = .37).
CONCLUSIONS: nPSA has been related to biochemical progression–free survival, freedom from metastasis, and death from prostate cancer. BT with either EBRT or HT achieves a lower PSA nadir. There was no difference in disease failure. Longer follow-up may be necessary to see differences in disease failure in this population.
Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
